Your browser doesn't support javascript.
loading
Resveratrol as a cardioprotective adjuvant for 5-fluorouracil in the treatment of gastric cancer cells
Liu, Lilong; Wang, Yexin; Dong, Yanyan; Lin, Shan; Guan, Wenhui; Song, Jia.
Affiliation
  • Liu, Lilong; The Fourth Affiliated Hospital of Harbin Medical University. Pharmaceutical Department. Harbin. CN
  • Wang, Yexin; Qingdao Mental Health Center. Pharmaceutical Department. Qingdao. CN
  • Dong, Yanyan; College of Basic Medical Sciences, Harbin Medical University. Harbin. CN
  • Lin, Shan; The Fourth Affiliated Hospital of Harbin Medical University. Pharmaceutical Department. Harbin. CN
  • Guan, Wenhui; The Fourth Affiliated Hospital of Harbin Medical University. Pharmaceutical Department. Harbin. CN
  • Song, Jia; The Fourth Affiliated Hospital of Harbin Medical University. Pharmaceutical Department. Harbin. CN
Braz. j. med. biol. res ; 57: e13537, fev.2024. graf
Article de En | LILACS-Express | LILACS | ID: biblio-1574228
Bibliothèque responsable: BR1.1
ABSTRACT
The clinical application of 5-fluorouracil (5-Fu), a potent chemotherapeutic agent, is often hindered by its well-documented cardiotoxic effects. Nevertheless, natural polyphenolic compounds like resveratrol (RES), known for their dual anti-tumor and cardioprotective properties, are potential adjunct therapeutic agents. In this investigation, we examined the combined utilization of RES and 5-Fu for the inhibition of gastric cancer using both in vitro and in vivo models, as well as their combined impact on cardiac cytotoxicity. Our study revealed that the co-administration of RES and 5-Fu effectively suppressed MFC cell viability, migration, and invasion, while also reducing tumor weight and volume. Mechanistically, the combined treatment prompted p53-mediated apoptosis and autophagy, leading to a considerable anti-tumor effect. Notably, RES mitigated the heightened oxidative stress induced by 5-Fu in cardiomyocytes, suppressed p53 and Bax expression, and elevated Bcl-2 levels. This favorable influence enhanced primary cardiomyocyte viability, decreased apoptosis and autophagy, and mitigated 5-Fu-induced cardiotoxicity. In summary, our findings suggested that RES holds promise as an adjunct therapy to enhance the efficacy of gastric cancer treatment in combination with 5-Fu, while simultaneously mitigating cardiotoxicity.
Mots clés

Texte intégral: 1 Indice: LILACS langue: En Texte intégral: Braz. j. med. biol. res Thème du journal: BIOLOGIA / MEDICINA Année: 2024 Type: Article / Project document

Texte intégral: 1 Indice: LILACS langue: En Texte intégral: Braz. j. med. biol. res Thème du journal: BIOLOGIA / MEDICINA Année: 2024 Type: Article / Project document